Lyon & Saint-Beauzire, France, June 28th, 2018 – NEURONAX, the biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic neurological disorders, will present its pre-clinical results highlighting the strong potential of its lead product NX210 during SfN‘s 48th annual meeting, Neuroscience 2018, the world’s largest neuroscience conference for scientists and physicians devoted to understanding the brain and nervous system. The congress will be held in San Diego, USA, from the 3rd to the 7th of November 2018.
Forum 2018 – Poster schedule:
Abstract Control Number: 6747
ABSTRACT TITLE: “Neurotrophic, anti-apoptotic and neuroprotective multifunctional activities of NX210, a thrombospondin repeat derived peptide”
Session Number: 210
Session Title: Neurotoxicity, Inflammation, and Neuroprotective Mechanisms: Preclinical
Date and Time: Sunday Nov 4, 2018 1:00 PM – 5:00 PM
Location: San Diego Convention Center: SDCC Halls B-H